has been cited by the following article(s):
[1]
|
Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection
Dermatologic Therapy,
2022
DOI:10.1111/dth.15274
|
|
|
[2]
|
New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management
Expert Review of Clinical Immunology,
2018
DOI:10.1080/1744666X.2018.1454835
|
|
|
[3]
|
Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab
Clinical Drug Investigation,
2018
DOI:10.1007/s40261-018-0671-z
|
|
|
[4]
|
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Journal of the American Academy of Dermatology,
2017
DOI:10.1016/j.jaad.2017.01.037
|
|
|